Indication
Locally Advanced Malignant Solid Neoplasm
16 clinical trials
27 products
8 drugs
Clinical trial
Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors With HER2 ExpressionStatus: Not yet recruiting, Estimated PCD: 2026-03-31
Product
AzenosertibProduct
Trastuzumab DeruxtecanClinical trial
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment TrialStatus: Recruiting, Estimated PCD: 2025-08-31
Product
IpatasertibDrug
TiragolumabClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamideProduct
Neoantigen Peptide VaccineClinical trial
A Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) in Combination With Everolimus in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in NSCLC Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) ExpressionStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
CeritinibProduct
EverolimusClinical trial
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-08-30
Drug
AdavosertibClinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseStatus: Recruiting, Estimated PCD: 2024-12-01
Product
TalazoparibProduct
PembrolizumabClinical trial
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-07-31
Drug
CeralasertibProduct
OlaparibClinical trial
Neoadjuvant Pembrolizumab for Patients With Mismatch Repair Deficient Locally Advanced Solid CancersStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmStatus: Active (not recruiting), Estimated PCD: 2023-10-04
Product
Antiretroviral TherapyClinical trial
Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2025-02-03
Product
AvapritinibProduct
DurvalumabClinical trial
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive TumorsStatus: Recruiting, Estimated PCD: 2025-11-11
Product
LarotrectinibClinical trial
A Combination Therapy for Cancer-Related Fatigue in Advanced Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Product
DexamethasoneClinical trial
A Phase I Trial of the P97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and LymphomasStatus: Withdrawn, Estimated PCD: 2021-07-12
Product
P97 Inhibitor CB-5339Clinical trial
Molecular Analysis for Combination Therapy Choice (ComboMATCH)Status: Recruiting, Estimated PCD: 2030-07-01
Drug
AlpelisibProduct
BinimetinibDrug
fluorouracilDrug
AlpelisibDrug
mFOLFOX6Product
NeratinibProduct
NilotinibProduct
PalbociclibProduct
PanitumumabProduct
SelumetinibProduct
SotorasibClinical trial
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant CancerStatus: Active (not recruiting), Estimated PCD: 2018-05-16
Product
DabrafenibProduct
TrametinibProduct
UprosertibClinical trial
The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 Agonist) in Combination With INCAGN01949 (an Activating Anti-OX40 Antibody) for In Situ Intratumoral Injection for Patients With Stage IV Pancreatic and Other Cancers Except MelanomaStatus: Terminated, Estimated PCD: 2022-12-19
Product
INCAGN01949Product
CMP-001